CLSA was greatly honored to welcome Dr. Robert Califf as the keynote speaker at our recent Evening with Thought Leaders in Los Angeles. Dr. Califf has had an extraordinarily impressive career as a cardiologist, Commissioner of the Food & Drug Administration (FDA), and now as a researcher with Duke University and advisor at Verily, an Alphabet company.
On Sept. 11, Senate Bill 790 (McGuire) was placed on the inactive file, meaning that, while the bill is dead for this year, it will be eligible to be heard again once the legislature reconvenes in early January 2018.
Despite the best efforts of CLSA and its partner trade associations, Senate Bill 17 (Hernandez) has reached the Governor’s desk. Gov. Brown has until Oct. 13 to sign the bill for it to become law. If it’s signed, the advance notice requirements, as discussed below, would become effective on Jan. 1, 2018.
On Sept. 12, the Sonoma Board of Supervisors held a new hearing on take back ordinance options for the County. At the Board’s last hearing on the subject in October of 2016, it had directed staff to begin drafting an ordinance for drug take back while also researching the potential need and possibility of including the disposal of sharps into the legislation.
CLSA hosts Congressman Tony Cárdenas (D-San Fernando Valley) for 3-days of tours at multiple life sciences sector companies and research institutions across the San Diego region.
CLSA has been working hard in opposition to the two biggest bills for the life sciences sector this year, Senate Bill 17 (Hernandez) and Senate Bill 790 (McGuire).
Assembly Bill 602 (Bonta), a bill sponsored by CLSA, was recently signed into law by Governor Jerry Brown. The law, which is already in effect due to an urgency clause, prohibits pharmacies from submitting insurance claims for diabetes test devices, such as blood glucose testing strips, acquired from unauthorized distributors.
Over 100 Cities and Counties throughout California have passed some form of restriction on the use of polystyrene (commonly referred to as “Styrofoam”) products over the last several decades. A new phase of local legislation on polystyrene with more restrictive measures is cropping up throughout the state.
With the first three-quarters of the year behind us, the remainder of 2017 will focus on raising the debt ceiling, preventing a government shutdown, and another top priority for the Trump Administration, tax reform.
As California’s legislature heads into its break for the summer, returning on Aug. 21, the top three bills of concern to the life sciences industry all face the potential for amendments before reaching their respective final floor votes.